Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Peginterferon and ribavirin treatment for hepatitis C virus infection Tsubota A; Fujise K; Namiki Y; Tada NWorld J Gastroenterol 2011[Jan]; 17 (4): 419-32Pegylated interferon alpha (IFNalpha) in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFNalpha and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients.|Antiviral Agents/*therapeutic use[MESH]|Disease Progression[MESH]|Genotype[MESH]|Hepacivirus/genetics[MESH]|Hepatitis C, Chronic/*drug therapy/pathology/physiopathology[MESH]|Humans[MESH]|Interferon alpha-2[MESH]|Interferon-alpha/*therapeutic use[MESH]|Liver Cirrhosis/drug therapy/pathology/physiopathology[MESH]|Polyethylene Glycols/*therapeutic use[MESH]|RNA, Viral[MESH]|Randomized Controlled Trials as Topic[MESH]|Recombinant Proteins[MESH]|Ribavirin/analogs & derivatives/*therapeutic use[MESH]|Treatment Outcome[MESH] |